The type 2 diabetes drug Invokana hit the market in 2013 with much hype. It was the first drug in a new class of diabetes treatments known as SGLT2 inhibitors. Johnson & Johnson and its unit Janssen Pharmaceuticals, stood to make millions – if not billions – from its novel new diabetes pill. Unlike other diabetes drugs that work through the pancreas or liver, SGLT2 inhibitors are metabolized through the kidneys and lower blood sugar levels by excreting excess sugar through the urine. Invokana, which contains the drug ingredient canagliflozin, proved to be a huge hit and remains a top seller ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.